Bill > A07409

This bill expands the definition of "opioid antagonists" across multiple New York state laws to include all forms and doses of Naloxone (a medication used to rapidly reverse opioid overdose) that have been approved by the Food and Drug Administration (FDA). The legislation requires the state Department of Health to make available all FDA-approved Naloxone formulations and dosages, and ensures that when purchasing, distributing, or prescribing opioid antagonists, entities can choose from any FDA-approved version. The bill amends several sections of New York's public health, mental hygiene, education, and insurance laws to consistently reflect this broader definition. For example, in the insurance law, insurers cannot discriminate against individuals prescribed opioid antagonists, and in the education law, advanced home health aides can administer pre-filled auto-injections of opioid antagonists. The bill aims to increase access to Naloxone and provide more flexibility in its use across various healthcare and emergency response settings, ultimately supporting efforts to combat opioid overdoses by making life-saving medication more readily available in different forms and dosages.

Health and Social Services

https://www.nysenate.gov/legislation/bills/2025/A7409